



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

24 May 2021 (#14)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

**Tygerberg Campus:** [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • **Stellenbosch Campus** [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. National Institute of Neurological Disorders and Stroke ([NINDS](#)) Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-21-237](#)

**Type:** UG3/UH3

**Application Due Date:** June 25, 2021; October 13, 2021; February 09, 2022; June 09, 2022 **Aids dates:** September 07, 2021; January 07, 2022; May 07, 2022; September 07, 2022. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (<https://www.ninds.nih.gov/>). For purposes of this FOA, the proposed study should be intended to prevent or treat a neurological disorder. This FOA will only support Phase 3 or Phase 4 clinical trials conducted to provide a definitive answer regarding the safety and efficacy of an intervention or to compare the effectiveness of two or more interventions. The proposed research must address a scientifically important question, provide valuable information to the existing knowledge base, and have public health relevance. The trial design should ensure that high quality, complete data regarding the primary outcome will be collected in the most efficient manner in terms of time, resources, and burden to subjects. Secondary outcomes should be included only when they are anticipated to provide important supportive or explanatory data. The necessity of each secondary endpoint must be justified in light of cost and burden. Pragmatic trials requiring minimal data collection and low cost per subject are encouraged. This FOA also may be used for the submission of an adaptive trial utilizing a seamless Phase 2/3 transition where data from subjects in Phase 2 are included in the analysis of Phase 3.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-TW-21-004](#)**

**Type: D43**

**Application Due Date:** August 20, 2021. Apply by 5:00 PM local time of applicant organization

**Funding Opportunity Announcement:** Although Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply, this is an opportunity to work with your collaborators in the USA. Only institutions and research sites in LMICs, as defined by the World Bank classification system (<http://data.worldbank.org/about/country-and-lending-groups>) and as restricted by [NOT-TW-12-011](#) 'Notice of Change in Country Eligibility for Fogarty International Training Grants', are eligible to participate; foreign trainees must be nationals of these eligible countries. The purpose of this program is to provide opportunities for up to six consortia to develop or expand global health research training programs that meet the following objectives: (1) provide one-year mentored research training for pre-doctoral students from the U.S. and recent post-doctoral and post-professional degree graduates (collectively referred to as trainees) from the U.S. and low- and middle- income countries (LMICs) in global health research at established biomedical and health research institutions and project sites in LMICs, particularly those supported by the NIH; (2) provide training opportunities within broad areas of research relevant to the health priorities of collaborating LMICs and aligned with the scientific priorities across the NIH Institutes, Centers, and Offices; (3) provide the solid scientific research foundation needed for trainees to rigorously develop and conduct research and effectively communicate research findings with increasing independence, with the goal of enhancing the global health research career potential of the trainees; and (4) provide more equitable access to and inclusive participation in this program to diverse populations in the U.S..

This Funding Opportunity Announcement (FOA) allows mentored training of trainees to serve as the lead investigator of an independent clinical trial or in a separate ancillary clinical trial, or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

**Budget:** The issuing IC and partner components intend to commit an estimated total of \$6.2 million in FY 2022 to fund up to six awards. Application budgets are limited to up to \$1 million in direct costs/year per award. The total project period for an application submitted in response to this Funding Opportunity Announcement may not exceed 5 years.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)  
Stellenbosch University  
2038 Wilcocks Building, Ryneveld Street  
Enquiries: *Lizél*  
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105